阿戈美拉汀治疗首发抑郁症患者的疗效及对认知功能的影响

Effect of agomelatine on first-episode depression and its influence on cognitive function

目的探讨阿戈美拉汀治疗首发抑郁症患者的疗效及对认知功能的影响。方法选取2015年1月~2017年1月我院收治的首发抑郁症患者100例作为研究对象,根据治疗方法不同随机分为观察组和对照组,每组各50例,对照组予盐酸帕罗西汀,观察组予阿戈美拉汀,治疗后,对两组患者的临床疗效进行评价,同时比较两组患者治疗前后认知功能中的视空间与执行、命名、记忆、注意、语言、抽象、延迟记忆、定向各项评分。结果治疗后,观察组患者治疗后的总有效率为88.0%,对照组的总有效率为80.0%,两组疗效比较,差异无统计学意义(P>0.05)。治疗前,两组患者认知功能中的视空间与执行、命名、记忆、注意、语言、抽象、延迟记忆、定向评分比较,差异无统计学意义(P>0.05)。治疗后,两组患者认知功能中的视空间与执行、命名、记忆、注意、语言、抽象、延迟记忆、定向评分分别较治疗前提高,且观察组各项认知功能评分显著高于对照组,差异有统计学意义(P<0.05)。结论阿戈美拉汀用于首发抑郁症患者的治疗中具有显著的临床疗效,且改善患者的认知功能,提高患者的生活质量,值得临床广泛推广和应用。

Objective To investigate the effect of agomelatine in treating first-episode depression and its influnce on cognitive function. Methods 100 patients with first-episode depression who were admitted in our hospital from January 2015 to January 2017 were selected as study subjects and randomly divided into observation group and control group with 50 cases in each group according to different treatment methods. The control group was treated with paroxetine hydrochloride and the observation group was given agomelatine. After treatment, the clinical efficacy between the two groups was evaluated. At the same time, the scores of visual space and executive, naming, memory, attention, language, abstraction, delay memory and orientation in the cognitive function between two groups before and after treatment were compared. Results After treatment, the clinical efficacy of the two groups was evaluated. The results showed that the total effective rate in the observation group and that in the control group was 88.0% and 80.0% after treatment. There was no significant difference in the total efficiency between the two groups（P〉0.05）. Before treatment, there was no significant difference between the two groups in cognitive function in terms of visual space and executive, naming, memory, attention, language, abstraction, delayed memory, and directional score. After treatment, visual space and executive, naming, memory, attention, language, abstraction, delayed memory and directed score in cognitive function in two groups were significantly higher than those before treatment. And the scores of cognitive function in the observation group were significantly higher than those in the control group. There was significant difference between the groups P〈 0.05）. Conclusion Agomelatine has significant clinical efficacy in the treatment of patients with first-episode dcpres- sion and can improve the cognitive function of patients and improve the quality of life of patients, which is worthy of widely clinical application